Mar 01, 2019 / 01:00PM GMT
Operator
Ladies and gentlemen, good day, and welcome to the ImmunoGen update conference call. Today's conference is being recorded.
At this time, I would like to turn the conference over to Ms. Sarah Kiely, Investor Relations. Please go ahead, ma'am.
Sarah Cue Kiely - ImmunoGen, Inc. - IR & Corporate Communications Officer
Thank you. Earlier today, we issued a press release summarizing top line Phase III FORWARD I results. This press release and the recording of the call can be found under the Investors & Media section of our website at immunogen.com.
On the call today are Mark Enyedy, our President and CEO; and Anna Berkenblit, our Chief Medical Officer.
During the discussion, we will use forward-looking statements and our actual results may differ materially from such statements. Descriptions of the risks and uncertainties associated with an investment in ImmunoGen are included in our SEC filings.
I'll now turn the call over to Mark.
Mark J. Enyedy - ImmunoGen, Inc. - President, CEO, Interim
ImmunoGen Announces Top-line Findings from the FORWARD I Trial Conference Call Transcript
Mar 01, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers